Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Relative Efficacy of Loteprednol (Lotemax®) vs. Loteprednol/Tobramycin (Zylet®) in Treatment of Chronic Ocular Surface Inflammation Associated With Meibomian Gland Dysfunction (MGD)/Posterior Blepharitis

NCT01456780 is registered in ClinicalTrials.gov with Massachusetts Eye and Ear Infirmary as lead sponsor.

NCT NCT01456780
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01456780 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Relative Efficacy of Loteprednol (Lotemax®) vs. Loteprednol/Tobramycin (Zylet®) in Treatment of Chronic Ocular Surface Inflammation Associated With Meibomian Gland Dysfunction (MGD)/Posterior Blepharitis
Lead sponsor
Massachusetts Eye and Ear Infirmary
Phase
Phase 4
Overall status
Completed
Start date
August 31, 2011
Completion date
June 30, 2017
Enrollment
60 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

meibomian gland dysfunction, posterior blepharitis